Dubberke Erik R, Reske Kimberly A, Seiler Sondra, Hink Tiffany, Kwon Jennie H, Burnham Carey-Ann D
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Antimicrob Agents Chemother. 2015 Aug;59(8):4533-43. doi: 10.1128/AAC.00642-15. Epub 2015 May 18.
Asymptomatic colonization may contribute to Clostridium difficile transmission. Few data identify which patients are at risk for colonization. We performed a prospective cohort study of C. difficile colonization and risk factors for C. difficile acquisition and loss in hospitalized patients. Patients admitted to medical or surgical wards at a tertiary care hospital were enrolled; interviews and chart review were performed to determine patient demographics, C. difficile infection (CDI) history, medications, and health care exposures. Stool samples/rectal swabs were collected at enrollment and discharge; stool samples from clinical laboratory tests were also included. Samples were cultured for C. difficile, and the isolates were tested for toxins A and B and ribotyped. Chi-square tests and univariate logistic regression were used for the analyses. Two hundred thirty-five patients were enrolled. Of the patients, 21% were colonized with C. difficile (toxigenic and nontoxigenic) at admission and 24% at discharge. Ribotype 027 accounted for 6% of the strains at admission and 12% at discharge. Of the patients colonized at admission, 78% were also colonized at discharge. Cephalosporin use was associated with C. difficile acquisition (47% of patients who acquired C. difficile versus 25% of patients who did not; P = 0.03). β-lactam-β-lactamase inhibitor combinations were associated with a loss of C. difficile colonization (36% of patients who lost C. difficile colonization versus 8% of patients colonized at both admission and discharge; P = 0.04), as was metronidazole (27% versus 3%; P = 0.03). Antibiotic use affects the epidemiology of asymptomatic C. difficile colonization, including acquisition and loss, and it requires additional study.
无症状定植可能会促进艰难梭菌的传播。很少有数据能确定哪些患者有定植风险。我们对住院患者进行了一项关于艰难梭菌定植以及艰难梭菌获得和清除风险因素的前瞻性队列研究。纳入了一家三级护理医院内科或外科病房收治的患者;通过访谈和病历审查来确定患者的人口统计学特征、艰难梭菌感染(CDI)史、用药情况以及医疗保健暴露情况。在入组时和出院时采集粪便样本/直肠拭子;还纳入了临床实验室检测的粪便样本。对样本进行艰难梭菌培养,并对分离株进行毒素A和毒素B检测以及核糖体分型。采用卡方检验和单因素逻辑回归进行分析。共纳入235例患者。其中,21%的患者在入院时被艰难梭菌(产毒和不产毒)定植,24%的患者在出院时被定植。核糖体分型027在入院时占菌株的6%,出院时占12%。入院时被定植的患者中,78%在出院时也被定植。使用头孢菌素与艰难梭菌获得有关(获得艰难梭菌的患者中有47%使用了头孢菌素,未获得艰难梭菌的患者中有25%使用了头孢菌素;P = 0.03)。β-内酰胺-β-内酰胺酶抑制剂联合用药与艰难梭菌定植清除有关(艰难梭菌定植清除的患者中有36%使用了该联合用药,入院和出院时均被定植的患者中有8%使用了该联合用药;P = 0.04),甲硝唑也是如此(分别为27%和3%;P = 0.03)。抗生素的使用会影响无症状艰难梭菌定植的流行病学情况,包括获得和清除,这需要进一步研究。